Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 22, 2021

SELL
$16.52 - $20.4 $26,630 - $32,884
-1,612 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$16.56 - $25.46 $1.76 Million - $2.7 Million
-106,124 Reduced 98.5%
1,612 $32,000
Q4 2020

Feb 08, 2021

BUY
$15.77 - $19.03 $234,973 - $283,547
14,900 Added 16.05%
107,736 $1.83 Million
Q3 2020

Nov 10, 2020

BUY
$16.59 - $24.79 $348,390 - $520,590
21,000 Added 29.23%
92,836 $1.62 Million
Q2 2020

Aug 13, 2020

BUY
$16.86 - $23.44 $379,350 - $527,400
22,500 Added 45.61%
71,836 $1.57 Million
Q1 2020

May 15, 2020

BUY
$14.47 - $27.96 $331,883 - $641,290
22,936 Added 86.88%
49,336 $1.03 Million
Q4 2019

Feb 12, 2020

SELL
$15.87 - $23.12 $55,132 - $80,318
-3,474 Reduced 11.63%
26,400 $584,000
Q3 2019

Nov 12, 2019

BUY
$16.91 - $36.27 $280,706 - $602,082
16,600 Added 125.06%
29,874 $501,000
Q2 2019

Aug 05, 2019

BUY
$31.0 - $36.3 $89,900 - $105,269
2,900 Added 27.95%
13,274 $414,000
Q1 2019

May 09, 2019

BUY
$31.58 - $46.35 $103,456 - $151,842
3,276 Added 46.15%
10,374 $334,000
Q4 2018

Feb 27, 2019

BUY
$30.43 - $56.65 $15,215 - $28,325
500 Added 7.58%
7,098 $286,000
Q3 2018

Dec 06, 2018

BUY
$46.46 - $68.49 $306,543 - $451,897
6,598 New
6,598 $251,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Burleson & Company, LLC Portfolio

Follow Burleson & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burleson & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Burleson & Company, LLC with notifications on news.